The Role of BRCA2 Mutation Status as Diagnostic, Predictive, and Prognosis Biomarker for Pancreatic Cancer

Table 1

Clinical trials for BRCA2 mutated pancreatic cancer patients.

Clinical trial	Phase	Study type	Drugs	Sponsor	Inclusion criteria
NCT02309632	Screening	Nonrandomized	Screening of high-risk individuals	University of Arkansas	Peutz-Jegher’s Syndrome
					BRCA1 mutation carrier
					BRCA2 mutation carrier
					Ataxia-telangiectasia
					Familial atypical malignant melanoma syndrome
					Colorectal neoplasms, hereditary nonpolyposis
					Hereditary pancreatitis
NCT02000089	Prospective observational	Cohort	Human synthetic secretin	Johns Hopkins University	Pancreas cancer
					Peutz-Jeghers Syndrome
					Gene mutation
					Germline mutation carrier
					Lynch Syndrome
NCT02775461	Prospective observational	Cohort	—	Icahn School of Medicine at Mount Sinai	Pancreas cancer
					Pancreatitis
					Chronic pancreatitis
					Pancreatic cyst
					Family history of pancreas cancer
					Genetic mutations
NCT01585805	Phase II	Randomized	Gemcitabine, cisplatin with or without veliparib or veliparib alone	National Cancer Institute	BRCA1 mutation carrier
					BRCA2 mutation carrier
					Metastatic pancreatic adenocarcinoma
					Pancreatic adenocarcinoma
					Recurrent pancreatic carcinoma
					Stage III pancreatic cancer
					Stage IV pancreatic cancer
NCT01102569	Prospective observational	Cohort	—	Columbia University	BRCA1 mutation carrier
					BRCA2 mutation carrier
NCT00438906	Prospective observational	Cohort	Human synthetic secretin	Johns Hopkins University	Pancreatic neoplasm
					Peutz-Jeghers Syndrome
NCT01233505	Phase I	Interventional	Veliparib, oxaliplatin, capecitabine	National Cancer Institute	Advanced solid tumors
					BRCA1 mutation carrier
					BRCA2 mutation carrier
NCT02703545	Prospective observational	Cohort	—	Johns Hopkins University	Peutz-Jeghers Syndrome
					Familial pancreas cancer
					BRCA1 mutation carrier
					BRCA2 mutation carrier
					Hereditary pancreatitis
NCT00714701	Prospective observational	Cohort	—	Sidney Kimmel Comprehensive Cancer Center	Early pancreatic neoplasia
					Familial pancreatic neoplasia
NCT00892736	Phase I	Interventional	Veliparib	National Cancer Institute	Advanced solid tumors
					BRCA1 mutation carrier
					BRCA2 mutation carrier
					Estrogen receptor negative
					HER2/Neu negative
NCT01339650	Phase I	Interventional	ABT-767	AbbVie	Advanced solid tumors
					BRCA1 mutation carrier
					BRCA2 mutation carrier
NCT01078662	Phase II	Interventional	Olaparib	AstraZeneca	Advanced solid tumors
					BRCA1 mutation carrier
					BRCA2 mutation carrier